HOME >> MEDICINE >> NEWS
Infectious disease expert to speak at American Academy of Ophthalmology's annual meeting

SAN FRANCISCO Gary N. Holland, MD, the David May II Professor of Ophthalmology at the University of California, Los Angeles, and Director of the Ocular Inflammatory Disease Center and the Clinical Research Center at the Jules Stein Eye Institute, will deliver the Jackson Memorial Lecture on the topic "Ocular Toxoplasmosis: A Global Reassessment" at the opening ceremonies of the Academy's Annual Meeting, Sunday, November 16, 2003, in Anaheim, Calif.

The Jackson Memorial Lecture is named after Edward Jackson, MD, who was professor and chairman of ophthalmology at the University of Colorado, president of the American Academy of Ophthalmology and Otolaryngology in 1903, and the first chairman of what is now the American Board of Ophthalmology.

Toxoplasmosis is a parasitic disease usually transmitted by ingestion of undercooked meat, especially lamb and pork, or unwashed vegetables contaminated with dirt containing cat feces. The parasite reproduces in the gut of the cat, but can infect many animals. Recently it has also been shown that some outbreaks of the disease were caused by contaminated drinking water, a previously unrecognized source of infection.

According to the Centers for Disease Control, "More than 60 million people in the United States probably carry the Toxoplasma parasite, but very few have symptoms because the immune system usually keeps the parasite from causing illness." Toxoplasmosis can be life-threatening in immunocompromised individuals, but even healthy individuals can have permanent vision loss, if the parasite gets into the eye. Ocular toxoplasmosis is the most common infection of the retina (the inner lining of the eye) in many parts of the world, including the United States.

Dr. Holland's address will describe advances in the understanding of ocular toxoplasmosis, since it was first recognized as a cause of blindness in adults 50 years ago. He also will use these advances in the understanding of toxoplasmo
'"/>

Contact: Media Relations
media@aao.org
415-561-8534
American Academy of Ophthalmology
28-Aug-2003


Page: 1 2

Related medicine news :

1. Infectious microorganism linked to kidney stones and other diseases
2. Infectious agent linked to mad cow disease found in organs other than the brain
3. The Lancet Infectious Diseases (TLID)
4. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
5. UCSDs Victor Nizet, M.D., receives Pediatric Infectious Diseases Award
6. The Lancet Infectious Diseases (TLID)
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. Infectious disease researcher available to discuss new federal recommendations aimed at protecting college students from meningococcal meningitis
10. New Model Shows How To Eradicate Worlds Leading Infectious Cause Of Blindness
11. First UK cases of previously rare disease reported in gay men

Post Your Comments:
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: